PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
Cavendish sees Poolbeg’s POLB 001 gaining strategic importance as CRS research expands
Greengage plans AQSE float with bold Bitcoin-backed lending strategy
Puretech gains after FDA meeting post-Phase II trial
Coinsilium notes Greengage’s plan to float on Aquis